|
 |
| EDITORIAL |
|
| Year : 2021 | Volume
: 12
| Issue : 4 | Page : 251 |
|
|
John studd—A tribute
Meeta Meeta1, Vishal R Tandon2
1 Department of Obstetrics and Gynaecology, Tanvir Hospital, Hyderabad, Telangana, India
2 Department of Pharmacology GMC Jammu, J&K, India
| Date of Submission | 01-Jan-2022 |
| Date of Decision | 05-Jan-2022 |
| Date of Acceptance | 07-Jan-2022 |
| Date of Web Publication | 20-Jan-2022 |
Correspondence Address:
Meeta Meeta
Department of Obstetrics and Gynaecology, Tanvir Hospital, Hyderabad, Telangana
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jmh.jmh_1_22
How to cite this article:
Meeta M, Tandon VR. John studd—A tribute. J Mid-life Health 2021;12:251 |
We dedicate this Editorial to the memory of Prof. John Studd, a legend in Menopausal Medicine. He is a fine example of a Physician–Scientist/Clinician–Researcher, which we had described in the previous Editorial. Prof. John Studd, in 1969 as a trainee, established the first menopause clinic at Birmingham in the United Kingdom, which was closed down by the local health authority, for Hormone replacement therapy (HRT) was considered unethical during that time. His passion and belief in managing mid-life led to reopening it as Midlands menopause clinic, which has been active to date.[1] As an astute clinician, Prof. Studd advocated menopausal hormone therapy (MHT) for the relief of menopausal symptoms, postmenopausal osteoporosis, reproductive depression, and libido. His uninhibited writings reflect his experience, research, and thought process on using MHT against the anti-MHT wave in the immediate aftermath post-Woman's Health Initiative (WHI) era. He wrote in 2005, on WHI, “This study is the wrong population, the wrong drug, and wrong conclusions as it is treatment in women whom we do not treat.” The chapter reflects Prof. Studd's acumen as a Clinician–Researcher, wherein his analysis does not agree with the immediate analysis report of WHI on MHT, and this perhaps came out of his real-world evidence and experience.[2]
Prof. Studd's landmark research in menopause includes using cyclical progestogen to avoid the risk of endometrial pathology versus the use of unopposed estrogen; skeletal response to estrogen is dose-dependent. He believed in MHT as a first line for preventing and treating postmenopausal osteoporosis. A significant contribution is promoting the concept of reproductive depression or estrogen-dependent mood disorders, which were treated inappropriately with antidepressants rather than HRT. He first described the use of estrogen patches and estrogen implants to treat severe premenstrual syndrome (PMS), postnatal depression, and perimenopausal depression. Prof. Studd's contributions toward the reproductive age group are well known. His series of books, Progress in Obstetrics and Gynecology, published annually between 1985 and 2008, are popular and formed an essential reference for the postgraduates appearing for recent advanced papers. He practiced up to 2019.
This issue features original articles related to bone health, a review on screening tools for osteoporosis in India, and one on dual-energy x-ray absorptiometry (DXA). Keeping in line with the articles on gender bias for diseases, we present to you an article on the influence of female sex hormones in different stages of women on periodontium. You will enjoy reading the sequelae to the pictorial review on endometrium at menopause, which features a pathologist, Meenakshi Swain's viewpoint. Happy reading!
Happy, healthy, and contended year ahead!
 References | |  |
| 1. | |
| 2. | Studd J. Progress in Obstetrics and Gynaecology. Vol. 16. Title, Progress in Obstetrics and Gynaecology, Volume 16. Publisher, Churchill Livingstone, London; 2005. p. 415.  |
|
